India's Pharma Sector Funding & M&A Deals: Key Deals (Apr 20-26)

India’s pharma sector funding, investment, mergers, and acquisitions activity during April 20–26 highlights a week shaped by mega M&A deals, strategic investments, and capital allocation moves.

From Sun Pharma’s global acquisition to AI-driven investment partnerships and biosimilars expansion, the period reflects how pharma companies are balancing scale, innovation, and financial discipline.

Funding & Investment Activity

Merck & Co. & Google Cloud: USD 1 Billion AI Push

Merck & Co. partnered with Google Cloud in a deal worth up to USD 1 billion to transform drug development through AI.

The partnership focuses on:

• Accelerating drug discovery timelines
• Improving manufacturing using predictive analytics
• Enhancing patient engagement with data-driven insights

The goal is simple—build a fully AI-enabled pharma enterprise.

iSERA Lifesciences Strengthens Capital Base

iSERA Lifesciences expanded its financial capacity during the week.

Key moves:

• Increased authorized capital
• Expanded borrowing/investment limits up to Rs 1,000 crore

This signals preparation for future investments, acquisitions, or expansion into biopharma.

Also Read: Role of Wellness in Corporate & Community Health

Aurobindo Pharma Announces Rs 800 Cr Buyback

Aurobindo Pharma initiated a Rs 800 crore share buyback.

Instead of deploying capital externally, the company chose to:

• Return value to shareholders
• Optimize its balance sheet

Funding & Investment – Companies Involved

Mergers & Acquisitions Activity

Sun Pharma Acquires Organon in USD 11.75B Mega Deal

Sun Pharmaceutical Industries announced the acquisition of Organon & Co. for ~USD 11.75 billion, marking one of the largest outbound deals by an Indian firm.

The deal:

• Adds 70+ products across 140 countries
• Strengthens presence in women’s health and biosimilars
• Positions Sun Pharma among top global players

Amneal Acquires Kashiv BioSciences for USD 1.1B

Amneal Pharmaceuticals announced a deal to acquire Kashiv BioSciences for up to USD 1.1 billion.

The acquisition aims to:

• Build a strong biosimilars pipeline
• Capture growth from biologics patent expiries

iSERA Lifesciences Acquires iSERA Biological

iSERA Lifesciences also acquired iSERA Biological for Rs 78 crore.

This move strengthens:

• Biologics capabilities
• Vertical integration within the group

Mergers & Acquisitions – Companies Involved

Key Trends This Week

• Mega consolidation is back: Sun Pharma’s deal reshapes global rankings
• Biosimilars are the next battleground: Seen in both Sun Pharma and Amneal moves
• AI is becoming core infrastructure: Not optional anymore (Merck deal)
• Capital discipline remains strong: Limited fresh funding, more strategic allocation